Bemfola 300 IE/0.5 ml Norge - norsk - Statens legemiddelverk

bemfola 300 ie/0.5 ml

orifarm as - follitropin alfa - injeksjonsvæske, oppløsning i ferdigfylt penn - 300 ie/0.5 ml

Insulin aspart Sanofi Den europeiske union - norsk - EMA (European Medicines Agency)

insulin aspart sanofi

sanofi winthrop industrie - insulin aspart - sukkersyke - legemidler som brukes i diabetes - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Nyvepria Den europeiske union - norsk - EMA (European Medicines Agency)

nyvepria

pfizer europe ma eeig  - pegfilgrastim - nøytropeni - immunostimulants, - reduksjon i varigheten av nøytropeni og forekomsten av febril nøytropeni hos voksne pasienter behandlet med cytotoksiske kjemoterapi for kreft (med unntak av kronisk myelogen leukemi og aml syndromer).

Bemfola 150 IE/0.25 ml Norge - norsk - Statens legemiddelverk

bemfola 150 ie/0.25 ml

orifarm as - follitropin alfa - injeksjonsvæske, oppløsning i ferdigfylt penn - 150 ie/0.25 ml

Bemfola 225 IE/0.375 ml Norge - norsk - Statens legemiddelverk

bemfola 225 ie/0.375 ml

2care4 aps - follitropin alfa - injeksjonsvæske, oppløsning i ferdigfylt penn - 225 ie/0.375 ml

Bemfola 300 IE/0.5 ml Norge - norsk - Statens legemiddelverk

bemfola 300 ie/0.5 ml

2care4 aps - follitropin alfa - injeksjonsvæske, oppløsning i ferdigfylt penn - 300 ie/0.5 ml

Byooviz Den europeiske union - norsk - EMA (European Medicines Agency)

byooviz

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - Øyemidler - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Zolsketil pegylated liposomal Den europeiske union - norsk - EMA (European Medicines Agency)

zolsketil pegylated liposomal

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Sondelbay Den europeiske union - norsk - EMA (European Medicines Agency)

sondelbay

accord healthcare s.l.u. - teriparatide - osteoporose - kalsiumhomeostase - sondelbay is indicated in adults. behandling av osteoporose hos postmenopausale kvinner og hos menn med økt risiko for brudd. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. behandling av osteoporose assosiert med vedvarende systemisk glukokortikoid terapi hos kvinner og menn med økt risiko for brudd.

Truvelog Mix 30 Den europeiske union - norsk - EMA (European Medicines Agency)

truvelog mix 30

sanofi winthrop industrie - insulin aspart - sukkersyke - legemidler som brukes i diabetes - truvelog mix 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above.